Trial Profile
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 15 Feb 2022 According to a Pfizer media release, European Medicines Agency (EMA) has approved the companys 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR.The EMA authorization for APEXXNAR is based on evidence from a clinical program in adults, including Phase 1 and 2 trials, and three Phase 3 trials (NCT03760146, NCT03828617, and NCT03835975).
- 08 Feb 2022 According to a Pfizer media release, the CHMP of the EMA issued a positive opinion recommending the granting of a marketing authorization for the pneumococcal 20-valent conjugate vaccine for the prevention of invasive disease and pneumonia caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults ages 18 years and older.
- 23 Dec 2021 Results published in the Clinical Infectious Diseases